[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas

.We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor. METHODS: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. RESULTS: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0±0.3 and 3.8±0.4 and TBRmean and TBRmax were 4.0±1.4 and 5.0±1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. CONCLUSION: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.

Abstract licence: CC BY

1. 1.

   CXCR4 over-expression and survival in cancer: A system review and meta-analysis · 2014

2. 10.

   PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand · 2011

3. 13.

   In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma · 2015

4. 26.

   G Protein-Coupled Receptors in Cancer · 2016

29 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.